Areef Kassam, MD
Psychiatry · Indianapolis, INNPI 1932561917
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,048 of the $9,893 with a category attached, or 61.1%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 78.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $4,624 and has fallen 50.3% since, to $2,299 in 2025. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $162.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$8K
- Alkermes, Inc.$571
- Otsuka America Pharmaceutical, Inc.$330
- Johnson & Johnson$290
- Teva Pharmaceuticals USA, Inc.$263
- AbbVie$188
- plus $502 from 10 others
What the payments were for
- Consulting fees$1,60016%
- Speaking & faculty fees$6,04861%
- Food & beverage$2,24523%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $7,748 |
| Alkermes, Inc. | 9 | $571 |
| Otsuka America Pharmaceutical, Inc. | 12 | $330 |
| Johnson & Johnson | 6 | $290 |
| Teva Pharmaceuticals USA, Inc. | 5 | $263 |
| AbbVie(2 entities) | 3 | $188 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $139 |
| E.r. Squibb & Sons, L.L.C. | 4 | $109 |
| Neurocrine Biosciences, Inc. | 3 | $78 |
| Lundbeck LLC | 2 | $47 |
| Noven Therapeutics, LLC | 2 | $35 |
| Indivior Inc. | 2 | $34 |
| Shire North American Group Inc | 1 | $16 |
| Neuronetics, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$910
- ARISTADA$443
- SPRAVATO$234
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- CAPLYTA$123
- VIVITROL$118
- UZEDY$117
- ARISTADA INITIO$111
- AUSTEDO$106
How this compares
$9,893 in reported general payments places this provider in the 90th percentile of 514 psychiatry providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 115 | $330,856 |
| Abilify MaintenaAripiprazole | 63 | $183,376 |
| Invega TrinzaPaliperidone Palmitate | 15 | $153,998 |
| AristadaAripiprazole Lauroxil | 34 | $111,666 |
| UzedyRisperidone | 21 | $100,751 |
| LybalviOlanzapine/Samidorphan Malate | 19 | $30,905 |
| Paliperidone ErPaliperidone | 30 | $19,250 |
| Ramelteon | 23 | $4,928 |
| Lurasidone Hcl | 19 | $4,492 |
| Clozapine | 40 | $2,905 |
| Olanzapine | 30 | $1,818 |
| Divalproex Sodium ErDivalproex Sodium | 25 | $1,806 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $964 |
| Risperidone | 37 | $474 |
| Aripiprazole | 39 | $455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $290 | $484,853130 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $330 | $183,37663 claims |
| Alkermes, Inc.Aristada, Lybalvi | $571 | $142,57153 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $263 | $100,75121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Indianapolis
- Charles BeasleyIndianapolis$129K
- Dmitry ArbuckIndianapolis$40K
- Albert AllenIndianapolis$24K
- Jerad DaltonIndianapolis$20K
- Alan BreierIndianapolis$19K
- Kristen DaussIndianapolis$16K
- Anantha ShekharIndianapolis$13K
- Maria ValenaIndianapolis$11K
- Robert BakerIndianapolis$11K
- Judi KnowlesIndianapolis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.